Wenbing Sun

Prof. Wenbing Sun


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
CYChangyu Yao
Changyu Yao
SWShilun Wu
Shilun Wu
JKJian Kong
Jian Kong
YSYiwen Sun
Yiwen Sun
YBYannan Bai
Yannan Bai
Lemin ZhengLemin Zheng
Lemin Zheng
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated death worldwide. Angiogenesis, the process of formation of new blood vessels, is required for cancer cells to obtain nutrients and oxygen. HCC is a typical hypervascular solid tumor with an aberrant vascular network and angiogenesis that contribute to its growth, progression, invasion, and metastasis. Current anti-angiogenic therapies target mainly tyrosine kinases, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), and are considered effective strategies for HCC, particularly advanced HCC. However, because the survival benefits conferred by these anti-angiogenic therapies are modest, new anti-angiogenic targets must be identified. Several recent studies have determined the underlying molecular mechanisms, including pro-angiogenic factors secreted by HCC cells, the tumor microenvironment, and cancer stem cells. In this review, we summarize the roles of pro-angiogenic factors; the involvement of endothelial cells, hepatic stellate cells, tumor-associated macrophages, and tumor-associated neutrophils present in the tumor microenvironment; and the regulatory influence of cancer stem cells on angiogenesis in HCC. Furthermore, we discuss some of the clinically approved anti-angiogenic therapies and potential novel therapeutic targets for angiogenesis in HCC. A better understanding of the mechanisms underlying angiogenesis may lead to the development of more optimized anti-angiogenic treatment modalities for HCC.

4 January 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
JKJian Kong
Jian Kong
CYChangyu Yao
Changyu Yao
SDShuying Dong
Shuying Dong
SWShilun Wu
Shilun Wu
YXYangkai Xu
Yangkai Xu
Lemin ZhengLemin Zheng
Lemin Zheng
Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) often leads to aggressive local recurrence and increased metastasis, and vascular integrity and platelets are implicated in tumor metastasis. However, whether interactions between endothelial cells and platelets induce endothelial permeability in HCC after insufficient RFA remains unclear. Here, significantly increased CD62P‐positive platelets and sP‐selectin in plasma are observed in HCC patients after RFA, and tumor‐associated endothelial cells (TAECs) activate platelets and are susceptible to permeability after heat treatment in the presence of platelets in vitro. In addition, tumors exhibit enhanced vascular permeability after insufficient RFA in mice; heat treatment promotes platelets‐induced endothelial permeability through vascular endothelial (VE)‐cadherin, and ICAM‐1 upregulation in TAECs after heat treatment results in platelet activation and increased endothelial permeability in vitro. Moreover, the binding interaction between upregulated ICAM‐1 and Ezrin downregulates VE‐cadherin expression. Furthermore, platelet depletion or ICAM‐1 inhibition suppresses tumor growth and metastasis after insufficient RFA in an orthotopic tumor mouse model, and vascular permeability decreases in ICAM‐1−/− mouse tumor after insufficient RFA. The findings suggest that ICAM‐1 activates platelets and promotes endothelial permeability in TAECs through VE‐cadherin after insufficient RFA, and anti‐platelet and anti‐ICAM‐1 therapy can be used to prevent progression of HCC after insufficient RFA.

21 October 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JGJun Gao
Jun Gao
RFRui-Fang Fan
Rui-Fang Fan
JYJia-Yin Yang
Jia-Yin Yang
YCYan Cui
Yan Cui
JJJian-Song Ji
Jian-Song Ji
WSWenbing Sun
Wenbing Sun
Radiofrequency ablation for hepatic hemangiomas: A consensus from a Chinese panel of experts

29 January 2022 in European Radiology
Verified
Journal Article
Closed access
PDF file
JKJian Kong
Jian Kong
RGRuize Gao
Ruize Gao
SWShilun Wu
Shilun Wu
YSYaoping Shi
Yaoping Shi
TYTao Yin
Tao Yin
JGJun Gao
Jun Gao

28 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
SWShilun Wu
Shilun Wu
RGRuize Gao
Ruize Gao
TYTao Yin
Tao Yin
RZRuhang Zhu
Ruhang Zhu
SGShigang Guo
Shigang Guo
WSWenbing Sun
Wenbing Sun
Purpose: To report the complications of radiofrequency ablation (RFA) for hepatic hemangioma.Patients and Methods: Investigators from six centers performed RFA for hepatic hemangioma and used a standardized follow-up protocol. Data were collected from 291 patients, including 253 patients with hepatic hemangioma 5 to 9.9 cm in diameter (group A) and 38 with hepatic hemangioma ≥ 10 cm (group B). Technical success, complete ablation, and complications attributed to the RFA procedure were reported. Analysis of variance was used to determine whether the major complication rate was related to tumor size or clinical experience.Results: A total of 304 lesions were treated in 291 patients. Technical success was achieved without adverse events in all cases. A total of 301 lesions were completely ablated, including 265 of 265 (100%) lesions in group A, and 36 of 39 (92.31%) in group B. The rate of technology-related complications was similar in groups A and B (5.14% (13/253) and 13.16% (5/38), respectively; P = 0.121). Moreover, all technology-related complications occurred during the early learning curve period. The rate of hemolysis-related complications in two groups were 83.40% (211/253) and 100% (38/38) (P =0.007) and the systemic inflammatory response syndrome-related complications in two groups were 33.99% (86/253) and 86.84% (33/38) (P<0.001). There were no delayed complications in either group.Conclusion: RFA is minimally invasive, safe, and effective for hepatic hemangiomas 5 to 9.9 cm in diameter. More clinical data are needed to confirm the safety of RFA for hepatic hemangiomas ≥ 10 cm.

17 July 2022 in International Journal of Hyperthermia
Verified
Journal Article
Open access
SDShuying Dong
Shuying Dong
ZLZhuxin Li
Zhuxin Li
JKJian Kong
Jian Kong
SWShilun Wu
Shilun Wu
JGJun Gao
Jun Gao
WSWenbing Sun
Wenbing Sun
Angiogenesis occurs during tumor progression of hepatocellular carcinoma (HCC) after insufficient radiofrequency ablation (RFA). Arsenic trioxide (ATO) shows promising therapeutic potential in adva...